

**REMARKS**

Restriction has been required under 35 USC§121 and 372 to elect a single invention to which the claims must be restricted:


- I. Claims 1 and 8 are drawn to a method for inducing or modulating T or B cell tolerance to donor cells tissue or organ.
- II. Claim 2 is drawn to a method for inducing hematopoietic chimerism in a recipient of cells, tissue or organ.
- III. Claim 3 is drawn to a method for treating diabetes.
- IV. Claim 4 is drawn to a method for inducing apoptosis.
- V. Claim 5 is drawn to a method for delaying progression of, attenuating severity or suppressing mitigating or treating immune disorder.
- VI. Claim 6 is drawn to a method for treating malignancies.
- VII. Claim 7 is drawn to a method for treating non-malignant diseases
- VIII. Claim 9 is drawn to a method for using LFA-1 inhibitor in combination with at least one co-agent.
- IX. Claims 10-12 are drawn to pharmaceutical composition comprising LFA-1 inhibitor and at least one co-agent.

Accordingly, Applicants elect Group II (claim 2) for further prosecution in this application.

New claim 13 depends from elected claim 2, and is directed to the method of claim 2. Thus, new claim 13 is within the same group as elected claim 2.

An early favorable action on the merits is respectfully requested.

Respectfully submitted,



\_\_\_\_\_  
Leslie Fischer  
Attorney for Applicants  
Reg. No. 58,393

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-9308

Date: Nov 27/07